SC10914

· Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for SC10914, covering 2017-12-06 to 2021-05-12. Get the full timeline:

Most recent: Clinical Trial Update: Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer [Phase 2]